Renhe Pharmacy Co (SZSE:000650) Net Income (Continuing Operations): ¥469 Mil (TTM As of Mar. 2026)


SZSE:000650 Renhe Pharmacy Co Ltd SZSE:000650
79 GF Score
Price ¥5.18
GF Value ¥4.99
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Renhe Pharmacy Co Net Income (Continuing Operations)?

Renhe Pharmacy Co SZSE:000650 -1.71% 79 Net Income (Continuing Operations) is ¥469 Mil as of Mar. 2026. GuruFocus rates SZSE:000650 with a GF Score™ of 79/100 and a GF Value™ of ¥4.99 (Fairly Valued). The stock has 1 warning sign investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Renhe Pharmacy Co's Net Income (Continuing Operations) for the three months ended in Mar. 2026 was ¥178 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥469 Mil.

Renhe Pharmacy Co  (SZSE:000650) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Renhe Pharmacy Co Net Income (Continuing Operations) Related Terms

Renhe Pharmacy Co Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Renhe Pharmacy Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renhe Pharmacy Co Net Income (Continuing Operations) Chart

Renhe Pharmacy Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 799.87 711.54 629.41 566.59 487.66

Renhe Pharmacy Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 196.74 158.51 113.87 18.55 178.23
SZSE:000650
79GF Score
Renhe Pharmacy Co Ltd SZSE:000650
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Renhe Pharmacy Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥469 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of ¥469 Mil mean?
Renhe Pharmacy Co (SZSE:000650) has a Net Income (Continuing Operations) of ¥469 Mil as of Mar. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Renhe Pharmacy Co and its competitors.
Is Renhe Pharmacy Co's Net Income (Continuing Operations) too high?
Renhe Pharmacy Co's current Net Income (Continuing Operations) is ¥469 Mil. Overall, Renhe Pharmacy Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Renhe Pharmacy Co's Net Income (Continuing Operations) compare to ZTS?
Renhe Pharmacy Co's Net Income (Continuing Operations) of ¥469 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Drug Manufacturers company?
A good Net Income (Continuing Operations) depends on the Drug Manufacturers industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Renhe Pharmacy Co and its competitors. Renhe Pharmacy Co's current Net Income (Continuing Operations) is ¥469 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renhe Pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Renhe Pharmacy Co (SZSE:000650) is currently considered Fairly Valued. The stock's GF Value™ is ¥4.99, compared to a current price of ¥5.18 — trading 3.8% above its estimated fair value. The current Net Income (Continuing Operations) is ¥469 Mil. Renhe Pharmacy Co's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Renhe Pharmacy Co (SZSE:000650), the current Net Income (Continuing Operations) is ¥469 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Renhe Pharmacy Co (SZSE:000650) Overvalued in 2026?

Based on GuruFocus' analysis, Renhe Pharmacy Co stock appears to be overvalued. The current stock price of ¥5.18 is trading 3.8% above its estimated GF Value™ of ¥4.99. GuruFocus considers Renhe Pharmacy Co to be Fairly Valued.

Key valuation signals for SZSE:000650:

  • Net Income (Continuing Operations): ¥469 Mil
  • GF Value™: ¥4.99 vs. price of ¥5.18 (3.8% above fair value)
  • GF Score™: 79/100 with 1 warning sign

No single metric tells the full story. See the SZSE:000650 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renhe Pharmacy Co Business Description

Address No. 998 Honggu Middle Avenue, Greenland Central Plaza, 18th Floor, Yuanchuang International, Zone B, Honggutan New District, Jiangxi Province, Nanchang, CHN, 330038
Renhe Pharmacy Co Ltd is a China-based company engaged in the production and sale of Chinese and Western medicines, raw materials, and health-related products, including oral solid dosage forms, oral liquid dosage forms, large-volume injections, small-volume injections, external washes, liniments, suppositories, ointments, and other dosage forms of pharmaceuticals and health-related products. The company's main products include: Renhe Kelike, Youkadan series, Fuyanjie series, Da Huo Luo capsules, Shanliang eye drops, Qinghuo capsules, and Zhengwei capsules.
79GF Score

Get the complete analysis for SZSE:000650

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.18
Price
¥4.99
GF Value